Pharmaceuticals, Biotechnology and Life Sciences
Swedish Orphan Biovitrum (Sobi) has entered into a 3-year agreement with Ireland’s Valeant Pharmaceuticals for the distribution of Ammonul injection, an acute Urea Cycle Disorders (UCDs) drug, in Europe, the Middle East and North Africa.
Botswana will be a centert for southern and east Africa for hematology-oncology treatment, as it will get a new $100…
Nicox, the international ophthalmic R&D company has presented preclinical results from its novel nitric oxide (NO) donating compound, NCX 667 at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting, held from February 16-19, 2017, in Florence, Italy.
Neovacs has signed with BioSense Global a commercial license option agreement for its IFNalpha Kinoid vaccine to treat lupus and dermatomyositis in China, worth up to €65 million in upfront and milestone payments, not including double-digit sales royalties.
Abzena has signed a deal with University College London (UCL) to manufacture Magacizumab, an antibody created with its ‘Abzena inside’ Composite Human Antibody technology.
Apitope’s ATX-MS-1467 has reduced the number and volume of brain lesions with a promising safety profile, the company said about results of a test.
The partnerships and deals struck at CPhI Russia have helped establish Russia at the forefront of pharmerging markets and it is expected to reach a value of $31.2 billion by 2019.
The growing incidence of more Western lifestyle diseases such as cardiovascular disease (CVD), cancer, diabetes and respiratory disease, in addition to infectious and parasitic illness, will present the pharmaceutical industry in Africa with a business opportunity of $40.8 billion in 2019.
Faron Pharmaceuticals has recruited first patient in the Phase II INFORAAA clinical trial of Traumakine for the treatment of Multi-Organ Failure (MOF) and mortality prevention of surgically operated Ruptured Abdominal Aorta Aneurysm (RAAA) patients.
Mereo BioPharma’s bone disease drug BPS-804 has been accepted to participate in the European Medicines Agency’s (EMA) Adaptive Pathways programme.